As the COVID-19 pandemic places a larger emphasis on the healthcare and pharmaceutical industry, MedTech firms are increasingly resorting to the capital market to raise funds for expansion, acquisitions, and cash requirements.
Vijaya Diagnostic Centre Limited, Glenmark Lifesciences Limited, Windlas Biotech Limited, Krsnaa Diagnostics, and Krishna Institute of Medical Sciences are among the leading ones.. Emcure Pharmaceuticals, Healthium Medtech Limited, Wellness Forever Medicare Limited, and Supriya Lifesciences Ltd are among the public companies in process.
Three businesses have filed papers with the Securities and Exchange Board of India (SEBI) for initial public offerings since September this year, Veeda Clinical Research Limited, Sahajanand Medical Technologies Limited, and Infinion Biopharma Limited (IPOs). Sahajanand Medical Technologies, located in Surat, aims to raise Rs 1500 crore, and Veeda Medical Research, based in Ahmedabad, Rs 831 crore.
Gujarat-based firms including Aashka Hospitals Limited, Ami Organics Limited, and Tatva Chintan Pharma Chem Ltd have already obtained cash through initial public offerings this year. Increased understanding of diagnostics, medical equipment, and treatments has improved the healthcare and pharmaceutical industries’ development prospects since the COVID-19 outbreak. Companies are seeking cash to fulfill the rising demands in the healthcare business, according to Vaibhav Shah, managing director of Monarch Networth Capital, a city-based financial services firm.
Firms are obtaining attractive values by listing their stock as the stock market soars on the strength of strong retail investor optimism.